OTHER (INCOME)/EXPENSE, NET - Narrative (Details) shares in Millions, $ in Millions	12 Months Ended			33 Months Ended
	Dec. 31, 2023 USD ($) lawsuit shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2026 USD ($) payment
Licensing Arrangement [Line Items]
Contingent consideration fair value adjustments	$ (8)	$ (9)	$ (542)
Celgene
Licensing Arrangement [Line Items]
Contingent consideration fair value adjustments			$ 513
Nimbus Therapeutics
Licensing Arrangement [Line Items]
License and other arrangements upfront payments	4,000
Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangement [Line Items]
Income from settlement		$ 40
Nimbus Therapuetics TYK2 Inhibitor | Nimbus Therapeutics
Licensing Arrangement [Line Items]
Income from settlement	$ 400
Change in control proceeds		10.00%
Percentage of ownership acquired	100.00%
Collaborative arrangement contingent payments maximum exposure	$ 2,000
AZ AB
Licensing Arrangement [Line Items]
Loss contingency, litigations, number | lawsuit	2
Litigation settlement, amount awarded from other party	$ 384
AZ AB | Forecast
Licensing Arrangement [Line Items]
Litigation settlement, amount awarded from other party				$ 560
Litigation settlement, number of payments | payment				4
Income from settlement				$ 418
BeiGene
Licensing Arrangement [Line Items]
Litigation settlement, number of shares transferred (in shares) | shares	23.3
Litigation settlement, expense	$ 322